Cefixime 50mg + Ofloxacin 50mg per 5ml With water
Paediatric dual-mechanism suspension combining a third-generation cephalosporin (Cefixime 50mg/5mL, cell wall synthesis inhibition via PBP binding) with a fluoroquinolone (Ofloxacin 50mg/5mL, DNA gyrase and topoisomerase IV inhibition causing lethal DNA strand breaks). Together these provide synergistic dual-mechanism bactericidal cover against gram-negative organisms, atypical pathogens, and fluoroquinolone-susceptible organisms including enteric fever pathogens. See FAMEFIX™ O Tablets for full mechanism detail.
Paediatric enteric fever (Salmonella typhi/paratyphi), complicated UTIs, traveller's diarrhoea, Shigellosis, and ENT infections with suspected resistant gram-negative pathogens. The suspension format is appropriate for older children above 5 years who cannot swallow tablets but require the dual cefixime-ofloxacin combination. Note: fluoroquinolones should be used judiciously in children; clinical benefit must outweigh risks.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
Enteric fever remains one of the most common serious bacterial infections in paediatric outpatient practice in India. The cefixime-ofloxacin combination targets both the intracellular and extracellular phases of Salmonella infection, and having this combination available as a paediatric suspension fills a genuine clinical need for children too young or unwilling to swallow tablets.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.